Duvakitug And Teva’s Growth: A Game Changer In Pharma

Summary:

• On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn’s disease and ulcerative colitis.
• However, a month and a half before this news, the Israeli pharmaceutical company pleased investors by once again beating analysts’ expectations by a wide margin.
• So, Uzedy’s sales amounted to $35 million in the third quarter of 2024, increasing more than 16 times year-on-year.
• Meanwhile, sales of Teva’s generics in North America reached $1.09 billion for the three months ended September 30, 2024, up 30.4% from the same period a year earlier.
• In addition to decreasing its net debt by more than $1 billion in the first three quarters of2024, in this article, you will discover why I continue to cover Teva Pharmaceuticals with a “Buy” rating.

Since the publication of my last article, “Teva’s Transformation: From Generics Leader To Branded Drug Innovator,” Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) stock price has risen by more than 25%. Despite the continued caution and even pessimism of

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.